Loading
A phase 2 trial of KL-A167, Carboplatin, Etoposide in small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB500 Combinations in Patients With Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07296809 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 80 participants planned, started 2026-01-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500 Powder for Injection, KL-A167 Injection, Carboplatin Injection, Etoposide Injection. Conditions listed: Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares KL-A167, Sichuan Kelun-Biotech.
Shares KL-A167, Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
Shares Etoposide, Carboplatin, Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Carboplatin.
Shares Sichuan Kelun-Biotech, Carboplatin.
Shares Sichuan Kelun-Biotech, Carboplatin, Small-cell lung cancer.
Shares Etoposide, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/